1. Uncovering the Right Sequence

3. Content Outline

4. Patient Case 1

5. Standard of Care for High-Risk, Locally Advanced Prostate Cancer

6. Is Local Treatment Helpful for High-Risk Prostate Cancer?

7. Confirming Benefit of Local Therapy in High-Risk Prostate Cancer

8. Treatment Intensification: Can We Improve Outcomes?

9. Patient Case 1 (cont)

10. Treatment Options for Non-Metastatic Prostate Cancer After Biochemical Relapse

11. Importance of Metastasis-Free Survival

12. Practical Considerations for Treatment Intensity

13. Toxicity Profiles of Anti-AR Therapies

14. Quality of Life Impact of AR-Targeted Therapy

15. Patient Case 1 (cont)

16. Issues Impacting Treatment Selection for Metastatic CRPC

17. Immunotherapy Options: Only in the United States

18. ERA 223 Radium-223 and Abiraterone Acetate and Prednisone in CRPC Patients

19. Patient Case 2

20. Defining High-Volume/High-Risk Metastatic Prostate Cancer

21. Chemotherapy for Metastatic Disease? Risk Status Matters

22. Updated Results Using First-Line Abiraterone

23. Local Radiotherapy for Metastatic Disease: STAMPEDE Outcomes Using CHAARTED Disease Volume Definition

24. High-Risk Patients: Abiraterone or Docetaxel?

25. Optimal Treatment Selection for Low-Volume Metastatic Disease

26. Patient Case 2 (cont)

27. Treatment Sequencing After Progression on First-Line Therapy

28. Informing Treatment Selection With Genetic Testing

29. Impact of Bone Health Agents on SSE Risk in ERA 223

30. Can We Prevent Skeletal Events Associated With Radium
Can We Prevent Skeletal Events Associated With Radium? Data From AR Inhibitor Trials

31. Key Takeaways

32. Abbreviations

33. Abbreviations (cont)